Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — Q3 2021 Earnings Presentation
15 slides from Xbrane Biopharma AB's earnings presentation, Oct 28, 2021
Slide 1: Interim Report January – September Financials
“The application to EMA marks yet another important milestone for Xbrane. The team, together with our colleagues at STADA, have worked relentlessly over recent months in preparing this filing. This milestone also represents a potentially important advancement for patients and families living with we
Slide 2: Disclaimer
Disclaimer You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in connection
Slide 3: Highlights in Q3 2021 incl. the Period After
Highlights in Q3 2021 incl. the Period After Submission of the Marketing Authorization Application for Xlucane to EMA Xlucane™: * — Positive top-line data from interim read-out of the ongoing Phase III equivalence study + Marketing Authorization Application to EMA (Europe) submitted and validated in
Slide 4: Key Milestones in the next months
Key Milestones in the next 12 months * Submission of Marketing Authorization Application to FDA for Xlucane™ * Sign agreements with additional partners for the sales and marketing of Xlucane™ + Upscaling the production process for Xcimzane™ and preparing for the start of clinical trials * Establish
Slide 5: Xlucane - Submission of Marketing Authorization Application during 2021
Xlucane™ - Submission of Marketing Authorization Application during 2021 2021 2022 Xlucane™ pivotal phase III trial 2023 Regulatory process EU and US July 2022 Lucentis® LoE EU e eee @ June 2021 'Nov2021 Q12022 Gmonthsinterim | LPI Full 12 top-line data i] month data 22 months Sep 2021 Q42021-Q1 202
Slide 6: Xbrane has a growing IP portfolio
Xbrane has a growing IP portfolio * Two new Patents granted in October for TIR Xbrane patents and patent applications (#) sequences for protein expression in E.coli 30 + Four new Patents granted in October protecting novel DNA sequences as part of gene construct resulting in a significant yield 20 i
Slide 7: Employees
Employees Number of Employees +58,8% Q/Q 54 45 40 36 30 : : 10 0 Q3 '20 Q4 '20 Q1'21 Q2 '21 Q3 '21 *) Parent Company only, previous quarters adjusted 54* YUBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS. Great Place i) Work. Certified Xbrane Biopharma ~57/43 Women and men in staff 50/50 Women and men in
Slide 8: Upcoming investor conferences
LSX Investial KEMPEN'S 18TH LONDON Jefferies London Redeye Showcase 2021 CONFERENCE Healthcare Conference Life Science Day London November 8-15, 2021 November 23-24, 2021 November 16–19, 2021 November 11, 2021 December 9, 2021 Malmö December 16, 2021 Stockholm
Slide 9: Slide 9
Slide 10: • control (power to obtain benefits from the asset) • future economic benefits (such
• • • • • • • control (power to obtain benefits from the asset) • future economic benefits (such as revenues or reduced future costs
Slide 11: • control (power to obtain benefits from the asset) • future economic benefits (such
• • • • • • control (power to obtain benefits from the asset) • future economic benefits (such as revenues or reduced future costs
Slide 12: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) 1 Q2 "21 Q3 "21 Total Company Expenses decreased with 20% in the Quarter. This as the reclassification of Xlucane in accordance with IAS 38 was put in effect as of July 1st, 2021 and valued at SEK 26.9m on the Balance Sheet in Q3. G&A costs in line with previous quarte
Slide 13: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Comparing like for like, total Operating Costs have increased with 25.5%. The total R&D costs (incl. Intangible Asset of SEK 26.9m) amount to SEK 63.4m, 88% of the total costs in the quarter. The Intangible Assets includes development costs related to the ongoing clini
Slide 14: Cash and Cash Equivalents; Shareholders' Equity
Cash and Cash Equivalents Shareholders’ Equity oo 500,0 , 4624 Aide ae 450,0 350 400,0 300 350,0 a 243,1 239,2 300,0 a 200 aaa 208.4 150 123.8 129.3 _ 135,0 ey ital 100,0 50 50,0 0 0,0 Q3'20 Q4'20 «tat 2213.21 a3'20 Q420 «121. 221 321 End of third quarter 2021 Cash amounts to 383,4 MSEK strengthened
Slide 15: Q&A